A detailed history of Exane Derivatives transactions in Uni Qure N.V. stock. As of the latest transaction made, Exane Derivatives holds 8 shares of QURE stock, worth $45. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8
Previous 8 -0.0%
Holding current value
$45
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 28, 2022

SELL
$20.24 - $36.01 $95,553 - $170,003
-4,721 Reduced 99.83%
8 $0
Q3 2021

Oct 26, 2021

SELL
$26.01 - $38.22 $1,196 - $1,758
-46 Reduced 0.96%
4,729 $151,000
Q2 2021

Jul 28, 2021

BUY
$29.97 - $37.17 $24,725 - $30,665
825 Added 20.89%
4,775 $147,000
Q1 2021

Apr 30, 2021

BUY
$29.24 - $42.03 $46,579 - $66,953
1,593 Added 67.59%
3,950 $133,000
Q4 2020

Jan 27, 2021

BUY
$35.35 - $50.67 $83,319 - $119,429
2,357 New
2,357 $85,000
Q1 2019

Apr 24, 2019

SELL
$27.39 - $68.41 $39,304 - $98,168
-1,435 Closed
0 $0
Q4 2018

Jan 31, 2019

BUY
$22.8 - $33.93 $32,718 - $48,689
1,435 New
1,435 $41,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $266M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.